Liquid Chromatography Tandem Mass Spectrometry Assay for Topiramate Analysis in Plasma and Cerebrospinal Fluid: Validation and Comparison With Fluorescence-Polarization Immunoassay

Summary The authors report the development and validation of a liquid chromatography tandem mass spectrometry assay (LC/MS/MS assay) for the analysis of topiramate (2,3:4,5-bis-o-(-1-methyl)-&bgr;-D-fructopyranose sulfamate) in plasma and cerebrospinal fluid (CSF). Comparison is made with the commercially available fluorescence-polarization immunoassay (FPIA). LC/MS/MS Assay Using the internal standard, 1,2:3,4-bis-o-(1-methylethylidene-&agr;-D-galactopyranose sulfamate), a structural isomer, the calibration curve in plasma was linear in the concentration range of 0.02–20.0 mg/L (r2 = 0.9998). The coefficients of variation in plasma were ≤ 3%, and the accuracy ranged from 100% to 101% in the therapeutically relevant concentration range of 0.4–16.0 mg/L. In CSF, the mean recovery was 98%, and there was linearity between the nominal and the estimated concentration in the range of 1.5–20.0 mg/L (r2 = 0.9996). FPIA The calibration curve was linear in the concentration interval of 1.6–24.3 mg/L (r2 = 0.9994), and the mean recovery was 96%. Accuracy in plasma was 99– 104%, and precision was 3.2–6.0%. In CSF, there was linearity between the nominal concentration and the estimated concentration in the range of 1.5–20.0 mg/L (r2 = 0.9995), and the mean recovery was 100%. Comparison Between FPIA and LC/MS/MS There was a high correlation between the FPIA and the LC/MS/MS assay (r2 = 0.9965 in plasma and r2 = 0.9996 in CSF, P < 0.001 for both). In plasma and CSF, the two methods showed equal results, evaluated as the ratio between the two methods (plasma: median ratio = 1.00; 95% confidence interval [CI], 0.98–1.02, paired-sample t test, P = 0.79; and CSF: median ratio = 1.00, 95% CI, 0.99–1.02, paired-sample t test, P = 0.75). The coefficient of variation on the ratios between the two methods had similar levels: 5% in plasma and 3% in CSF. Conclusion The new LC/MS/MS assay has favorable characteristics, being highly precise and accurate. FPIA also proved precise and accurate, and there was a high agreement with the LC/MS/MS assay in plasma and CSF. Either method displayed sufficient precision and accuracy and may thus be implemented in daily routine.

[1]  M. Dam,et al.  Plasma Concentration of Topiramate Correlates With Cerebrospinal Fluid Concentration , 2001, Therapeutic drug monitoring.

[2]  P. Carvey,et al.  Validation of liquid-liquid extraction followed by flow-injection negative ion electrospray mass spectrometry assay to Topiramate in human plasma. , 2001, Rapid communications in mass spectrometry : RCM.

[3]  J. Djurhuus,et al.  [The GCP-unit at the Aaarhus University Hospital]. , 2000, Ugeskrift for laeger.

[4]  P. Patsalos,et al.  Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. , 2000, Therapeutic drug monitoring.

[5]  T. Glauser,et al.  Controversies in Blood‐level Monitoring: Reexamining Its Role in the Treatment of Epilepsy , 2000, Epilepsia.

[6]  T. Glauser,et al.  An improved gas chromatography assay for topiramate monitoring in pediatric patients. , 2000, Therapeutic drug monitoring.

[7]  E. Perucca,et al.  Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants? , 2000, Clinical pharmacokinetics.

[8]  T. Glauser,et al.  Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial , 2000, Epilepsia.

[9]  G. Montouris,et al.  Nonfocal Generalized Tonic–Clonic Seizures: Response During Long‐Term Topiramate Treatment , 2000, Epilepsia.

[10]  G. Pledger,et al.  Topiramate as Add‐On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults , 2000, Epilepsia.

[11]  T. Tomson,et al.  Therapeutic monitoring of the new antiepileptic drugs , 2000, European Journal of Clinical Pharmacology.

[12]  P. Carvey,et al.  Rapid approach to the quantitative determination of topiramate (2, 3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry. , 1999, Rapid communications in mass spectrometry : RCM.

[13]  G. Lensmeyer,et al.  Therapeutic monitoring of topiramate: evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method. , 1999, Therapeutic drug monitoring.

[14]  M. Privitera.  Evidence‐based Medicine and Antiepileptic Drugs , 1999, Epilepsia.

[15]  R. Shank,et al.  In vivo microdialysis and liquid chromatography/thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate) in rat brain fluid. , 1998, Journal of mass spectrometry : JMS.

[16]  G. Pledger,et al.  Topiramate Monotherapy for Partial Onset Seizures , 1997, Epilepsia.

[17]  J. Sackellares,et al.  Safety and Efficacy of Divalproex Sodium Monotherapy in Partial Epilepsy , 1997, Neurology.

[18]  G. Pledger,et al.  Topiramate as Adjunctive Therapy in Refractory Partial Epilepsy: Pooled Analysis of Data from Five Double‐Blind, Placebo‐Controlled Trials , 1997, Epilepsia.

[19]  E. Ben-Menachem.  Clinical Efficacy of Topiramate as Add‐On Therapy in Refractory Partial Epilepsy: The European Experience , 1997, Epilepsia.

[20]  A. Marson,et al.  New antiepileptic drugs: a systematic review of their efficacy and tolerability , 1996, BMJ.

[21]  J. Sackellares,et al.  Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. , 1997, Neurology.

[22]  E. Ben-Menachem,et al.  Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy , 1996, Epilepsy Research.

[23]  E. Ben-Menachem,et al.  Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures , 1996, Epilepsia.

[24]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages , 1996, Neurology.

[25]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages , 1996, Neurology.

[26]  M. Brodie,et al.  New antiepileptic drugs—an explosion of activity , 1995, Seizure.

[27]  P. Genton,et al.  Panic Attacks Mistaken for Relapse of Epilepsy , 1995, Epilepsia.

[28]  M. Holland,et al.  Automated capillary gas chromatographic assay using flame ionization detection for the determination of topiramate in plasma. , 1988, Journal of chromatography.

[29]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[30]  Josemir W Sander.  New Drugs for Epilepsy , 1985, The Lancet.

[31]  J S Krouwer,et al.  How to improve estimates of imprecision. , 1984, Clinical chemistry.

[32]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.